IXICO PLC (LON:IXI), the brain imaging group that uses AI analytics, has been chosen by a current client to provide neuroimaging services for a phase III clinical trial.
The latest contract is worth £500,000 over four years and will see the group participate in a neuroinflammatory disorder study.
Chief commercial officer Lammert Albers: "By bringing together our company's proven therapeutic expertise, advanced AI analytics and robust operational infrastructure, IXICO will enable this existing biopharmaceutical client to accelerate research and development decision making, de-risk clinical research and maximise the value of their CNS drug development pipelines.”
This latest agreement and an April 28 contract support an acute ischemic stroke programme diversify IXICO’s expertise into new areas, the firm said.